Details

Autor(en) / Beteiligte

• Kang, Huapyong
• Han, Sung Yong
• Cho, Jae Hee
• Kim, Eui Joo
• Kim, Dong Uk
• Yang, Jae Kook
• Jeon, Soyoung
• Park, Goeun
• Lee, Tae Hoon

Titel

Efficacy and safety of temperature‐controlled intraductal radiofrequency ablation in advanced malignant hilar biliary obstruction: A pilot multicenter randomized comparative trial

Ist Teil von

• Journal of hepato-biliary-pancreatic sciences, 2022-04, Vol.29 (4), p.469-478

Ort / Verlag

Japan: Wiley Subscription Services, Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose We aimed to evaluate the efficacy and safety of temperature‐controlled intraductal radiofrequency ablation (ID‐RFA) for advanced malignant hilar biliary obstruction (MHBO). Methods Patients were randomly assigned to RFA group (ID‐RFA and bilateral plastic stent [PS]) or non‐RFA group (bilateral PS) at a 1:1 ratio. Exchange to self‐expanding metal stent (SEMS) was performed after 3 months or when premature PS occlusion occurred. Total event‐free stent patency, overall survival (OS), and adverse events (AEs) were analyzed. Results A total of 30 patients from three hospitals were enrolled. Stent patency and OS did not differ between the two groups (178 days vs 122 days, P = .154; 230 days vs 144 days, P = .643; respectively). In patients with each stricture length ≥11 mm on both sides, stent patency was longer in the RFA group than in the non‐RFA group (175 days vs 121 days, P = .028). More patients received elective exchange to SEMS without PS occlusion in the RFA group than in the non‐RFA group (69.2% vs 23.1%, P = .018). AE rates did not differ between the two groups. Conclusions Temperature‐controlled ID‐RFA for advanced MHBO was safe and feasible. It could prevent premature PS occlusion within 3 months. Kang and colleagues conducted a pilot randomized controlled trial comparing temperature‐controlled intraductal radiofrequency ablation plus stent placement with stent placement alone in advanced malignant hilar obstruction. Intraductal radiofrequency ablation was safe and feasible, resulted in a lower rate of premature stent occlusion, and may help patients receive scheduled stent exchange.